Aparecida De Goi�nia, Brazil
- Featured
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Condition: COVID-19 Treatment: Fostamatinib / Placebo Clinical Study Identifier: NCT04629703
Phase
3Span
Sponsor
Rigel Pharmaceuticals, Inc.Sao Jose Do Rio Preto
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Phase
3Span
222 weeksSponsor
GlaxoSmithKlineSao Jose do Rio Preto
Recruiting
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
Phase
4Span
260 weeksSponsor
GlaxoSmithKlineSao Jose do Rio Preto, São Paulo
Recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Phase
3Span
336 weeksSponsor
Janssen Research & Development, LLCSao Jose do Rio Preto
Recruiting
Sao Jose do Rio Preto
Recruiting
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Up to 5 years
Phase
3Span
245 weeksSponsor
SanofiSao Jose do Rio Preto, São Paulo
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
The primary endpoint of interest in this study is time to next treatment (TTNT), a measure that will determine how long T-DXd allows patients to derive clinical benefit from the study drug.
Phase
3Span
196 weeksSponsor
Daiichi SankyoSao Jose do Rio Preto
Recruiting
Roll-over Study to Allow Continued Access to Ribociclib
The purpose of this study is to evaluate long-term safety and provide continued treatment to participants who are currently receiving ribociclib in combination with other drugs in a parent study, that has fulfilled requirements for its primary objective(s), and in the opinion of the Investigator, would benefit from continuing treatment at time of discontinuation from the parent study
Phase
4Span
293 weeksSponsor
Novartis PharmaceuticalsSao Jose do Rio Preto
Recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Phase
3Span
468 weeksSponsor
Regeneron PharmaceuticalsSao Jose do Rio Preto
Recruiting